NASDAQ:APTXAptinyx Stock Price, Forecast & News

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APTX stock has increased by 48.6% and is now trading at $3.61. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptinyx.

Aptinyx is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Aptinyx.

Aptinyx Inc (NASDAQ:APTX) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.01. The firm had revenue of $0.82 million for the quarter, compared to analyst estimates of $0.91 million. Aptinyx had a negative return on equity of 47.99% and a negative net margin of 1,540.42%. View Aptinyx's earnings history.

6 Wall Street analysts have issued 1 year price targets for Aptinyx's stock. Their forecasts range from $7.00 to $12.00. On average, they expect Aptinyx's stock price to reach $8.67 in the next twelve months. This suggests a possible upside of 140.1% from the stock's current price. View analysts' price targets for Aptinyx.

News articles about APTX stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aptinyx earned a news impact score of 3.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutAptinyx.

Some companies that are related to Aptinyx include Ardelyx (ARDX), Provention Bio (PRVB), Homology Medicines (FIXX), G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), Assembly Biosciences (ASMB), Morphic (MORF), ZIOPHARM Oncology (ZIOP), DiaMedica Therapeutics (DMCAF), Stemline Therapeutics (STML), Trillium Therapeutics (TRIL), Radius Health (RDUS), Syndax Pharmaceuticals (SNDX), Passage Bio (IMRA) and Frequency Therapeutics (FREQ). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Square (SQ) and vTv Therapeutics (VTVT).

(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Aptinyx's stock is owned by many different institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (2.55%), Ikarian Capital LLC (1.30%), BlackRock Inc. (0.94%), Sphera Funds Management LTD. (0.90%), Geode Capital Management LLC (0.45%) and JPMorgan Chase & Co. (0.45%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen. View institutional ownership trends for Aptinyx.

APTX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, and Squarepoint Ops LLC. View insider buying and selling activity for Aptinyx.

APTX stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Ikarian Capital LLC, Sphera Funds Management LTD., Geode Capital Management LLC, Acadian Asset Management LLC, BlackRock Inc., JPMorgan Chase & Co., and Bank of New York Mellon Corp. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach, and Torsten M Madsen. View insider buying and selling activity for Aptinyx.

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APTX stock can currently be purchased for approximately $3.61.

Aptinyx has a market capitalization of $164.82 million and generates $3.67 million in revenue each year. The company earns $-57,410,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

The official website for Aptinyx is www.aptinyx.com.

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]